Tetradecyl Sulfuric Acid

Summary

Tetradecyl Sulfuric Acid (CHEMBL1201345) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 294.45 Da · C14H30O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201345
Name	Tetradecyl Sulfuric Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	8771
ChEBI	CHEBI:75275
Molecular formula	C14H30O4S
Molecular weight	294.45
InChIKey	GROJOWHVXQYQGN-UHFFFAOYSA-N

SMILES: CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)O

IUPAC name: (7-ethyl-2-methylundecan-4-yl) hydrogen sulfate

ChEBI definition: An alkyl sulfate that is the mono-7-ethyl-2-methylundecan-4-yl ester of sulfuric acid.

Also known as: Tetradecyl sulfate, SID29218059, SODIUM TETRADECYL SULFATE

Parent form; salt/anhydrous children: CHEMBL1200354

Patent coverage: 36 distinct patent families (92 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 87 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06106971	PHASE3	UNKNOWN	Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding
NCT05597995	PHASE2	UNKNOWN	Treatment of Epidermoid Cysts
NCT04655417	EARLY_PHASE1	UNKNOWN	is Ultrasound-guided Foam Sclerotherapy a Cost-effective Alternate for Treatment of Varicose Veins?
NCT03363633	Not specified	TERMINATED	Perforator Vein Injection for Symptomatic Venous Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).